Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ-ARWR) is a healthcare company in the biotechnology industry, and NASDAQ-ARWR is a common stock security on the NASDAQ exchange. The company develops RNA interference-based medicines intended for serious diseases, with research efforts that span multiple therapeutic areas and stages of development. Its work also includes collaborative arrangements with other drug makers. This security represents common equity in a biotech issuer, so its value depends on the company’s research progress, clinical results, regulatory outcomes, and broader market conditions. Investors should view it as a listed equity tied to a development-stage pharmaceutical business rather than a commercial product company.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARWR
|
$66.97
|
-10.0% Downside
|
Fair
|
$96
|
29.1% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-34.7x
|
17.0x
|
16.8x
|
10.092 B
|
10.035 B
|
12.1%
|
87.2%
|
3.3
|
—
|
16.9%
|
